Stock Market Today: Trump Media Shares Soar, Investors Watch More Earnings
Major indexes are on track for their worst month of the year.
Source: newsweek.com
📰 Davida Ricks News
Page 2 - Davida Ricks News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Davida Ricks. Real-time updates on events, politics, business and more.
Eli Lilly and : Q1 Earnings 2024 Press Release
April 30, 2024 For Release: Immediately Refer to: Jordan Bishop; jordan.bishop@lilly.com; 473-5712 Joe Fletcher;...
Source: marketscreener.com
Eli Lilly's Zepbound and Mounjaro sales are booming
The pharma giant's sales grew 26% year over year, driven by sales of Mounjaro and Zepbound
Source: qz.com
Eli Lilly (LLY) earnings Q1 2024
Zepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.
Source: cnbc.com
Eli Lilly Stock Surges as Weight Loss Drugs Continue to Fuel Growth
Drugmaker Eli Lilly's stock jumped Tuesday morning as weight loss drugs Mounjaro and Zepbound continue to boost revenue and profits.
Source: investopedia.com
AstraZeneca CEO's big pay package to receive shareholder vote
AstraZenca shareholders are set to vote on CEO Pascal Soriot's pay package
Source: qz.com
Top 10 Companies in the World: Full List
Market capitalization for companies is usually calculated based on the value of its shares. The value is influenced by stock price and the overall compa
Source: albawaba.com
American pharma major Eli Lilly's big focus on India: Will the company's strategy work?
American pharma major Eli Lilly sees India as its launchpad for a new growth trajectory, using its new drugs for diabetes and obesity as the fuel. Will this strategic pivot work? - Issue Date: Mar 31, 2024
Source: businesstoday.in
Anti-obesity drugs drive revenue growth for Eli Lilly in Q4 2023
Revenue from 'New Products', primarily driven by these medications, saw a significant 219% year-over-year increase, reaching $2.49 billion
Source: businesstoday.in
Zepbound soars in first quarter on market as Eli Lilly rides GLP-1 wave
Zepbound, which recently received approval for treating obesity from the FDA, notched nearly $176 million in its first quarter on the market.
Source: mmm-online.com